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Sunmanr A total of 164 consecutive adults with newly confirmed stage IIIB. IVA or IVB Hodgkin's disease
(HD) commenced cychcal combination chemotherapy comprising mustine. vinblastine. prednisolone and
procarbazine (MVPP) every 6 weeks (145 patients) or minor variants (19) at St Bartholomew's Hospital
between 1968 and 1984. The median follow-up period is 14 years. Complete remission (CR) was achieved in
97 164 (5900) and partial remission (PR) in 23 164 (14%) with lesser responses or death being documented in
44. Achievement of CR correlated with stage. serum albumin and serum A microglobulin level at presentation
on univariate and multivariate analysis: 55 97 (58%) remain in continuous CR. the median duration of
remission not having been reached. Twelve patients died in first remission: there have been 30 recurrences. one
occumng after 13 years. Second remission was achieved in 17 30: 6 17 remain in continuous second remission
and two have died in second remission. There have been nine second recurrences, third remission being
achieved in 6 9. Two continue in third remission, two patients have died in third remission: 82 164 patients are
alive with a minimum follow-up of 6 years. Eighty-two patients have died: 66 with evidence of HD, six with
second malignancy. one each of haemorrhage and infection. eight of unrelated causes, the cause of death was
unknown in one. The overall median survival from presentation is 14 years. being the same for patients in CR
and PR with minimal residual abnormality (good partial remission. GPR). and being better for those for
whom remission was achieved than those for whom it was not. The median survival following first recurrence
is 4 years. being significantly longer for younger patients (< 50 years). These results emphasise the importance
of long-term follow-up to determine the clinical course of HD and are vital for planning experimental
chemotherapy at the time of early treatment failure or recurrence.
The overwhelming improvement in the prognosis of
advanced Hodgkin's disease (HD) brought about by the
introduction of 'MOPP'-like cyclical combination
chemotherapy appropriately led to this becoming established
as the chemotherapy of choice for the ensuing two decades
(DeVita et al.. 1970: Nicholson et al.. 1970: Sutcliffe et al..
1978: Longo et al.. 1986; Hancock. 1986; McKendrick et al..
1989: Selby et al.. 1990; Ranson et al.. 1991). In the mean-
time. the drawbacks of the treatment have become gradually
apparent. It fails. to some extent. for at least one-third of the
patients. either because remission. the major prerequisite for
improving on the natural history is not achieved, or because
recurrence occurs. It is unpleasant to receive and there are
long-term complications of infertility (Chapman et al.. 1979:
1981: Horning et al.. 1981) and development of second
malignancy (Coleman. 1986; Dorreen et al.. 1986; Tucker et
al.. 1988: Kaldor et al.. 1990). Within the context of the only
alternative being death following sequential single agent pal-
liation. all of this was quite acceptable. The discovery of new
drugs. the formulation of new combinations and the demons-
tration that bone marrow ablative therapy may be supported
successfully. however, have inevitably raised questions as to
whether the initial strategy should be modified. with the
obvious objectives of decreasing the failure rate. or at least
maintaining the proven level of success with less toxicity.
This analysis is presented to complement the relative
paucity of reports on long-term follow-up of patients treated
with a MOPP vanrant at the initial presentation with
advanced HD. and provide a larger background against
which to assess alternative approaches.
Materials and methods
Patients
A total of 164 consecutive previously untreated adults with
advanced (stage IIIB. IVA. IVB) Hodgkin's disease were
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referred to the department of Medical Oncology. St Bar-
tholomew's Hospital. London between 1968 and 1984. and
form the basis of this analysis. The diagnosis was confirmed
in all instances by one of us (AGS) and re-reviewed to
incorporate further subdivision of nodular sclerosing HD.
and staging was according to the Ann Arbor classification
(Carbone et al.. 1971)' modified to include the use of com-
puted axial tomography as an alternative to lymphography
for the detection of intra-abdominal disease from 1980.
Clinical details of the patient population are shown in
Tables I and II.
Serum. stored at -20'C from 1978 onwards from initial
presentation was available in 60 cases. These cases were not
selected in any other way. A double antibody radioim-
munoassay (Pharmacia) was used to quantify A microg-
lobulin levels in these specimens.
Treatment at presentation
Chemotherapy Between 1968 and early 1984. the treatment
of choice was cyclical combination chemotherapy With mus-
Table I Patient population
Male:Female 122:42
Age years Range 13-79
Median 36
CS PS
Stage IIIB 61 33 28
IVA 28 15 13
IVB 75 64 11
Histologs NSI 47
NSII 46
LP 10
MC 37
LD 15
NHL and HD I
Unclassified 8
Total 164 112 52
NS = nodular sclerosing-subclassified into type I and II accord-
ing to BNLI classification: LP = lymphocyvte predominant:
MC = mixed cellularity: LD = lymphocyte depletion:
NHL = non-Hodgkin's lvmphoma; CS = clinically staged:
PS = pathologically staged.
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Table II Sites of extranodal disease
Site Frequency
Liver 37
Bone Marrow 17
Bone 12
Lung 8
Liver + bone marrow 8
Liver + lung 6
Liver + central nervous system I
Bone + lung 3
Lung + hver + bone
Bone marrow + bone
Gut
Lung + thyroid 1
Central nervous system
Skin 1
Peritoneum 1
Day 1
Mustine
6mg m .v.
Vinblastine
6 mg m i2v* v
Day 8
El
zzzzz\\zzzzzzzzl ......... ..... ...............ZZZZZZZZ\\\ss
.....zProcarbazine 100 mg m-2 p. "Ilzz llzzzlsj\ss\\\\s\\vs\sssjxjssjj\jjvjj
:: rednisgo Ione 40mg p g p o
tine. vinblastine. prednisolone and procarbazine (MVPP), the
intention being that responding patients should receive a
minimum of si'x cycles at 6-weekly intervals (Figure 1). A
total of 133 patients commenced MVPP during this time.
with seven having chlorambucil substituted for mustine and
the therapy being given at 4-weekly intervals (ChlVPP),
because of advanced age and frailty. Other minor
modifications were made to the treatment for 13 patients.
and one was treated for high grade non-Hodgkin's lym-
phoma because of concurrent HD and immunoblastic lym-
phoma.
For the latter part of 1984, all patients received ChlVPP
electively (n = 10).
With the passage of time, the total amount of treatment
prescribed for each patient declined, as the results of trials
became available. From 1968 until 1970 it was planned that
all patients should receive 16 cycles of therapy. at increasing
intervals over 3 years; from 1970 till 1974 patients entering
complete remission were randomised to receive two drug
(vinblastine and procarbazine, 13 patients) or four drug
(MVPP. 11 patients) maintenance. For the final 10 years, six
cycles was considered adequate.
Dose The ratio of cumulative therapy administered to plan-
ned therapy over the first six cycles was retrospectively cal-
culated in the patients for whom remission was achieved
(Appendix). Delays in administration of chemotherapy were
also evaluated in this group. The dose:time analysis showed
that 85% of the patients received more than 85% of the
therapy on time (Figure 2).
Radiotherapy Twenty-four of 164 patients received irradia-
tion electively in addition to the chemotherapy, eight prior to
chemotherapy, becuase of pressing clinical problems (in these
patients, the response to MVPP has not been distinguished
from that of radiotherapy) and 16 after completion of
chemotherapy, to sites of previous bulk disease or persistent
residual abnormality. The response to radiotherapy has been
documented separately for the latter.
Definition of response
This has been documented at the completion of six cycles of
chemotherapy, unless death or obvious progression had
intervened. The criteria upon which the description of the
response are based changed over the 22 years of study, the
precision with which 'complete remission' can be defined
having increased. Consequently, the distinction between com-
plete remission (CR) and partial remission (PR) has changed.
To accommodate this, PR was subdivided as described
below. It is important to note that GPR is not necessarily
equivalent to the newly designated CR(u)(Lister et al., 1989).
Complete remission (CR) A state when the patient is well,
with no clinical or radiological (or other) evidence of Hodg-
kin's disease.
Cycles repeated every 6 weks, day 1 to day 1
Fge I MVPP treatment schedule.
MVPP dose intensity (cycles 1-6)
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Figre 2 Dose:time curve of administered chemotherapy.
Partial remission. [i] Good partial remission (GPR). A state
when the patient is clinically well. but with persisting
minimal residual abnormality at the completion of therapy.
These patients were treated as if they were in clinical remis-
sion and observed without further therapy, as for complete
remitters.
[ii] Poor partial remission (PPR). A state when the
patient is well with residual abnormality, with a minimum
reduction of more than 50% estimated volume of Hodgkin's
disease.
Failure Any response less than partial response.
Earl} death Death occurring during the period of therapy.
precluding an assessment of response.
Duration ofremission
This has been defined as the period from documentation of
remission to recurrence or, for patients in continuous remis-
sion, to time of last clinic attendance. For patients whose
initial response was GPR, this period is the time to clinical
progression recurrence.
Treatment of recurrence
Recurrence after MVPP was usually retreated with combina-
tion chemotherapy, though the regimens have inevitably
altered over the years. Recurrences which occurred during
the early years of the study were retreated with MVPP,
Day 14
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MOPP or Ch1VPP. Non-cross resistant regimens such as
adnramycin (doxorubicin). bleomycin. vinblastine and DTIC
(ABVD) or etoposide. vincristine and adriamycin (EVA)
were investigated from 1978 onwards (Sutcliffe et al., 1979:
Richards et al., 1986). Irradiation. either singly or in com-
bination with chemotherapy was used as necessary.
Precision of documentation of extent of disease and res-
ponse to therapy declined with repeated recurrence, further
response being described as remission (CR and GPR) or less.
Follow-up
The median follow-up for the study is 14 years. with a
minimum follow-up of 6 years.
Follow-up information was complete and correct on 160
patients. either to death or until Autumn 1990.
Statistical analysis
Proportions of patients achieving CR in different prognostic
groups were compared using the r test with Yates's correc-
tion (Armitage. 1971). Duration of remission and overall
survival were plotted using standard life table methods (Kap-
lan & Meier. 1958) and compared using the log rank method
(Peto et al.. 1977). The significance of prognostic factors in
determining the achievement of CR was evaluated by logistic
regression analysis. whereas duration of CR and overall sur-
vival differences were determined using a stepwise linear
regression method based on Cox's proportional hazards
model (Cox. 1972).
Results
Initial Presentation
Response to therapy Complete remission (CR) was achieved
in 97 164 (59%) by the completion of six cycles of therapy.
Nine of these patients had received adjuvant radiotherapy.
Partial remission (PR) was achieved in 23 164 (14%). with
18 23 being subclassified as GPR (18 164=I11%). the other
five being PPR. Four patients whose response was GPR after
chemotherapy received irradiation with subsequent complete
resolution of the abnormality in two. All five patients whose
initial response was PPR received further therapy (non-cross
resistant regimens in three. combined modality therapy in
one and further MVPP in one). with complete resolution of
the residual disease in two and minimal residual abnormality
(GPR) in a third.
Twenty-nine patients (18%) had a response less than PR
following six cycles of MVPP. Twenty-four of these pro-
ceeded to further therapy [MVPP MOPP (seven), alternative
chemotherapy (16) or combined modality therapy (one)], CR
being subsequently achieved in only one; a second patient
was left with minimal residual disease (GPR) (Table III). One
patient refused further therapy and two died of progressive
disease before treatment was initiated. One patient died
postoperatively, following restaging laparotomy and splenec-
tomy.
The total number of patients in whom CR was achieved
with first line (97) and second line (five) therapy was 102 164
(62%).
Fifteen patients died before completion of planned treat-
ment. before response to treatment could be adequately
assessed; three were known to have advancing disease at the
time of death. There were nine deaths due to infective comp-
lications. one of cardiac failure. one from pulmonary
embolus and one from cardiac tamponade due to
haemopericardium.
The effects of presentation age. gender. serum albumin.
erythrocyte sedimentation rate (ESR), alkaline phosphatase,
lymphocyte counts. B symptoms. drug dose intensity, his-
tology and serum 2 microglobulin on achievement of remis-
sion were determined by univanrate and multivariate analyses
(the A microglobulin results were from a smaller set of
patients).
Prognostic factors significant for the achievement of CR by
logistic regression analysis were albumin (P = 0.0002) and
stage (IIIB vs IV. P = 0.004) (Table IV). The CR rate in-
creased with increasing albumin. from 36% (13 36) for
albumin <33 g 1. to 61% (46 76) for albumin 33-39 g 1. to
81% (34 42) for albumin 40 g 1. The CR rate for patients
stage IIIB disease was 75% compared with 50% in patients
with stage IV disease. Stage and albumin were independent.
unrelated factors. significant on multivariate analysis.
Table III Response to second line therapv in non-remitters
Response No. retreated Response to second line
to initial Number and regimen CR GPR PPR FAIL
MVPP
GPR 18 4-RT 2 2
PPR 5 1-MVPP I
3-NCR 1 1 1
1-RT + CCNU I
Total (PPR group) 2 1 1 1
FAIL 29 24
7-MVPP
16-NCR I I
I -RT + MVPP 1
Total (Fail group) 1 1 1
RT= radiotherapy, NCR = non-cross-resistant regimen
Table IN Prognostic factors for remission induction
Prognostic
Factor
Albumin
gI
Stage
microglobulin
fsg ml
Age
Sex
ESR
Alkaline
phosphatase
Lymphocyte
count
B symptoms
Histology
NS = not significant
Remission
rate% b!
groups
36
61
81
75
50
64
29
Significance
-univariate
P)
<0.001
<0.001
0.002
0.04
Variable
<33g I
33-39g I
>40g I
IIIB
IV
<3>fig ml
3 + g ml
<40:40 +
vears
M:F
<40:40 +
Normal vs
abnormal
<0.75 x1091
>0.75 x109 1
Significance
multivariate
,PJ
0.0002
0.004
0.02
NS
NS
NS
NS
NS
NS
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On a reduced set of 60 patients with known 2 microg-
lobulin values, selected only for the fact that serum had been
stored at presentation, using the logistic regression method.
1 microglobulin was the only significant factor for achieve-
ment of CR (P = 0.02). The CR rate in patients with serum
1 microglobulin levels in the normal range (0-31ig,ml) was
23/36 (64%). in contrast to 7 24 (29%) in individuals with
elevated levels (>3pg,ml). This difference is highly
significant on univariate (P = 0.002) and multivariate analysis
(P = 0.02).
Age is significant by univanrate analysis (P = 0.04). but is
correlated with albumin and is not significant in the mul-
tivariate analysis. Lymphocyte count. histology. ESR.
alkaline phosphatase and sex did not correlate with achieve-
ment of CR.
First remission - CR Fifty-five of 97 patients entenrng CR
with six cycles of therapy remain in continuous remission, the
median duration of first remission not having been reached
(Figure 3). Twelve patients died in first remission. Recurrence
has been documented in 30 between 0 and 13 years. Patients
in GPR had a significantly higher 'recurrence rate compared
with patients who achieved CR (P<0.001) (Figure 3). recur-
rence being documented in 15 18.
In these (remitters) patients. retrospective calculation of
the cumulative dose administered [Appendix] demonstrated
on univariate analysis. a significantly higher risk of recur-
rence. if there was a reduction of more than 15% of the
planned cumulative dose over the first six cycles (P = 0.009).
However, the duration of remission was the same for
patients who received maintenance chemotherapy after six
cycles when compared with patients treated with six cycles
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Figre 4 Survival of patients with advanced Hodgkin's disease
A = uncensored; B = censored for second malignancy deaths
only; C = censored for all non-Hodgkin's disease deaths.
only. There was no significant difference in remission dura-
tion of patients receiving two drug maintenance, compared to
patients receiving four drug maintenance. (This has been
previously reported as part of a multicentre Medical
Research Council trial - MRC Working Party on Lym-
phomas. 1979.)
There is no significant difference in the duration of remis-
sion of patients who had additional irradiation. compared
with patients who had chemotherapy alone.
Presentation age. gender, albumin. serum . microglobulin.
erythrocyte sedimentation rate (ESR). alkaline phosphatase.
lymphocyte counts. B symptoms did not correlate with remis-
sion duration on univariate analyses.
Recurrent disease
Thirty patients had recurrent disease. Second CR was
achieved in 17 30 and PR in two, with what was considered
appropriate therapy (Table V). Overall. salvage therapy with
non-cross-resistant regimens was more effective than MVPP
type regimes at inducing second remission (Table VI)). The
median duration of second remission is 4.3 years. Nine of
those 17 who achieved second remission have had a second
recurrence. third remission being reinduced in six. the median
duration of third remission being 4.4 years.
Fifteen of the 18 patients in GPR have had recurrent
progressive disease. Complete remission was induced in nine
patients with appropnrate salvage therapy (Table V) and
GPR in a further three.
Response at first recurrence correlated with duration of
first remission - remission (CR and GPR) was induced in
54% of patients whose first remission was less than 1 year.
63% when remission was between 1 and 2 years and 88%
when remission greater than 2 years (Table VI). There was
no correlation between age. gender. albumin level or ex-
tranodal disease at recurrence and achievement of second
remission (or duration of second remission). Over a 15-year
period. a significantly greater proportion of patients with
recurrence within 2-3 years of second remission had duration
of first remission of less that 12 months (P = 0.01). However.
there was no overall correlation between duration of first
remission and duration of second remission.
Table V Response to salvage therapy in patients with recurrent
disease
Response
to initial Salvage Nwnber Response to salvage
therapy regimen retreated CR GPR PPR
CR MVPP Type 12 5
NCR 5 4 1
RT 8 7
Combined modalitv 2 1 1
No treatment 3
Total 30 17 1 1
GPR MVPP type 8 4 2 1
NCR 5 4 1
Surgery 1 I
No treatment I
Total 15 9 3 1
NCR= non-cross-resistant therapy: ABVD = Sutcliffe et al. (1979)
EVA = Richards et al. (1986).
Tabl VI Efficacy of salvage therapy related to time to recurrence
Time
Interval Total MVPP NCR RT Other
<I year 7 13 38 1 1 22 1 2
1-2years 10 16 46 5 5 2 3 0 3
>2 years 14 16 6 7 5 5 3 3
Total 3145 1221 11 11 7 8 1 5
.HIJ
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Survival from initial presentation
Eighty-two of 164 patients are still alive, the overall median
survival being 13.7 years (Figure 4). Eighty-two patients have
died; 66 patients had active HD at the time of death. 42
never having been in clinical remission (CR or GPR). The
median survival of the non-remitters, excluding early deaths.
is 0.4 years (0.2 years, including early deaths) (Figure Sa).
Though the numbers are small, the survival of patients who
achieve clinical remission with second line therapy or require
more than six cycles of MVPP is significantly worse than
patients who achieve clinical remission with initial
chemotherapy (P = 0.004). The survival of patients in CR is
the same as for patients in GPR, despite a significantly
higher rate of recurrent disease in the latter (Figure Sb).
Fifty-five of the 97 patients entering CR are alive without
ever having had a recurrence, 6!97 are alive having had one
recurrence, four having had two recurrences and one having
had three recurrences. Thirty-one of the 97 remitters are
dead, 12 never having had a recurrence. 15 with recurrence
once, three twice and one three times (Figure 6).
Sixteen patients died without clinical evidence of Hodg-
kin's disease at the time of death. 12 never having recurrent
disease, four following recurrence and being in second (two)
or third remission (two).
There was no significant difference in survival of patients
treated with MVPP compared with patients treated with
ChlVPP.
The stepwise linear regression method was used to detect
any differences in survival correlating with age, sex, stage.
histology, albumin, alkaline phospatase, absolute lymphocyte
count or ESR. The only factors which significantly affect
survival adversely on univariate and multivariate analysis are
advanced age. histology (lymphocyte deplete) and low
absolute lymphocyte count (<0.75 x I1091) (Table VII).
Albumin failed to reach statistical significance (despite its
importance for achievement of CR) though it correlates
highly with lymphocyte deplete histology (mean albumin in
patients with lymphocyte deplete histology is 31 g,1 compared
to 37 g/1 in patients with other histology (P = 0.001, t-test)
and low absolute lymphocyte count. Similarly, stage cor-
relates with age (mean age in stage IIIB patients was 34
years, compared to 42 years for stage IV patients (P= 0.001,
t-test)). Stage and albumin did not, therefore reach statistical
significance in the multivanrate analysis.
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Figwe 5 a, Survival of remitters * non-remitters * patients who
achieve remission with second line therapy. b. Survival of patients
in CR v GPR PR.
Figure 6 Flow diagram of patterns of remission and recurrence.
Table Vita Univariate analysis of prognostic factors for survival
Variable Significance-P value
Albumin 0.002
Age <45:46 + <0.001
Lymphocyte count <0.75:0.75 x 10 1 0.009
Histology LD:rest <0.001
Pmicroglobulin 0.003
Stage IIIB:IV 0.01
Maintenance chemotherapy 0.1
ChIVPP:MVPP 0.4
Chemotherapy:combined modahty 0.66
Table VIIb Multivariate analysis of prognostic factors for survival
Non HD and
Non HD second
deaths malignancv
All deaths censored deaths censored
Prognostic factor RR P RR P RR P
Age (<45: >45years) 3.1 0.0001 2.4 0.002 2.4 0.003
Histology (LD vs rest) 2.3 0.03 2.6 0.01 2.6 0.02
Lymphocyte count 1.9 0.03 1.9 0.04 2.1 0.03
(<0.75 vs>0.75 x 109 1)
Sex, stage, albumin. Pmicroglobuhn. alkaline phosphatase and ESR were not
significant on multivanrate analysis. RR = relative risk, LD = lymphocyte depletion
histology.
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On the reduced set of 60 patients with known P2 micro-
globulin levels, age and lymphocyte count were again
significant. Serum R microglobulin was significant on
univariate (P = 0.003, Figure 7), but not on multivariate
analysis.
On the basis of these prognostic factors, patients can be
divided into two distinct groups-a good prognostic group.
in which none of the patients have any of the adverse factors
(age less than 45 years, lymphocyte count more than
0.75 x 1091 and histology apart from lymphocyte depletion).
and a poor prognostic group, where patients have one or
more of the adverse factors. The difference between the two
groups is statistically very significant (P<0.001) (Figure 8).
Survivalfollowing recurrence The median survival from first
recurrence is 4 years, being better when second remission was
achieved than the rest. The median survival of patients who
achieve second CR is 12 years. Advanced age correlated
adversely with survival, (age greater than 40. P = 0.04; age
greater than 45, P<0.009; age greater than 50, P = 0.009).
Extranodal disease at time of recurrence was a significant
adverse prognostic factor on univariate but not on mul-
tivariate analysis. Gender, albumin level at recurrence or
duration of first remission were not significant in correlating
for better survival.
Causes ofdeath
Eighty-two of the original 164 patients have died, 15 before
completion of planned chemotherapy and 51 with refractory
or recurrent disease. Thus 66/82 (80%) of the deaths occur-
red in patients with evidence of active disease. There were 16
l°rT.
!7-,
deaths in patients who had no evidence of active disease at
the time of death, six of which were due to second malig-
nancy.
The causes of death are shown in Table VIII. Details of
deaths of patients who died with no evidence of HD are in
Table IX.
Second malignancies Second malignancies have been
recorded in 10 patients (Table X), six having died as a result.
The commonest second malignancy has been non-Hodgkin's
lymphoma; there has been only one documented case of
acute myeloid leukaemia. Of the 67 patients in continuous
first remission. seven have developed a second malignancy.
Three of the seven had maintenance chemotherapy (24
patients had maintenance chemotherapy in total): three
others had irradiation in addition to the chemotherapy (21
remitters received irradiation overall). There was one second
malignancy in second remission and one in third; one patient
developed acute leukaemia with concurrent progressive
disease at second recurrence.
Discwho
This analysis provides further evidence of the enormouse
long-term survival advantage conferred on patients with
advanced Hodgkin's disease by the achievement of complete
remission with MOPP-like cyclical combination
chemotherapy, with more than 50% of them predicted to be
alive 20 years later. and only one recurrence having been seen
to date, after 10 years. In contrast. the survival of those for
whom no remission was achieved was as bad as the natural
history of the disease.
From this perspective. the first urgent prion'ty is an imp-
rovement of the complete remission rate. This was lower
(59%) with MVPP than has been recorded by others with
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Figre 8 Survival of patients with Hodgkin's disease, by prog-
nostic group. Good prognostic group:age <45 years and lym-
phocyte count more than 0.75 x 109/1 and histology apart from
lymphocyte depletion. Poor prognostic group:either age >45
years or lymphocyte count <0.75 x 109/1 or lymphocyte deplete
histology.
Table VIII Causes of death
Hodgkin's disease present 66(15)a
Second malignancy 6( 10)b
Cerebrovascular accident
Myocardial infarction 3
Infection 3
Coma I
Unknown
'Early deaths, btotal second malignancN
Table IX Causes of deaths in remission
Time from
Age at Which Diagnosis
Patient death remission Cause (ivears)
IDG 51 First Coma 8 months
2AN 62 First NHL CVA 3
3DS 61 First CVA 7
4EA 54 First Oat cell carcinoma of 7.5
bronchus
SGH 76 First Bronchopneumomna old 8
age (age 76 years)
6PL 47 First Adenocarcinoma of 9 years
lung
7CG 34 Third Myeloproliferative 11
disorder
8BAJ 72 First Carcinoma of the 11
prostate
9BC 42 Third Myocardial infarction 13
IOAG 58 First Unknown 13.8
I ICRW 80 First Bronchopneumonima 14
12AE 46 First Myocardial infarction 14.3
13WPG 65 Second ? second malignancy 15.3
(Histology
inconclusive)
14JAB 72 First Myocardial infarction 17.5
15RDH 60 First Carcinoma of the 18
oesophagus
16COL 49 Second Non-Hodgkin's 20
lymphoma
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Table X Second malignancies
Time from
Second Remission diagnosis
malignancy status Treatment XYears
NHL Second CR MVPP. COPP. 13.8
CVPP
NHL First CR MVPP MRT 12.6
NHL First CR MVPP maintenance 10.5
Carcinoma of First CR MVPP MRT 10
oesophagus
Squamous cell First CR MVPP MRT 9.4
carcinoma of
skin and
carcinoma of
the prostate
Myelodvsplastic Third CR MVPP maintenance 9.4
syndrome
Adenocarcinoma First CR MVPP + TNI 9
of lung
Oat cell First CR MVPP 6.4
carcinoma of
lung
Acute mveloid Progressise MVPP 3.1
leukaemia disease at
second
recurrence
NHL First CR MVPP maintenance 2.8
NHL = non-Hodgkin's lImphoma. MRT = mantle radiotherapy.
TNI = total nodal irradiation. COPP = cyclophosphamide. *incnr-
stine. procarbazine and prednisolone: CVPP = cyclophosphamide.
vinblastine. procarbazine and prednisolone.
MOPP or similar regimens (Longo et al.. 1986: Selby et al..
1990: Ranson et al.. 1991). although some of the difference
may be accounted for by variations in the patient popula-
tions, particularlv with respect to age and general debility (as
reflected by hypoalbuminaemia). additional therapy or
differences in the criteria for documenting complete remis-
sion. Regardless of this. however. it is clear that either persis-
ting with the same treatment beyond six cycles, or changing
it at that time to an alternative is not a fruitful approach
since this only increased the complete remission rate to 620o.
and more important. the survival of this 6% was markedly
inferior to that of the initial 5900. Failure to demonstrate
significant efficacy of the ABVD programme (Santro &
Bonadonna. 1979) for patients with refractory disease at St
Bartholomew's Hospital. in contrast to the experience in
Milan (Santoro et al.. 1979: 1982). may well relate solelv to
the fact that it was 'left too late'. The equivalent efficacy of
the ABVD and MOPP in inducing remission provided the
rationale for testing non-cross-resistant and hybrid combina-
tions (Santoro et al.. 1982: Klimo & Connors. 1985). Most.
but not all. recent data have supported this approach for
improving responsiveness. the most spectacular results com-
ing from Vancouver. with a reported complete remission rate
of 88% (Klimo & Connors. 1988) after hybrid chemotherapy
and involved field irradiation where necessary. Failure to
achieve complete remission in this way. of course. leaves little
room for manoeuvre and raises the question of whether bone
marrow ablative treatment is indicated for some patients in
this setting. The present consensus seem to be that it is only
likely to benefit those who are at least showing some
evidence of response (Jagannath et al.. 1989: Carella et al..
1988): dose escalation per se does not universally overcome
intrinsic resistance. Clearly some indication from the presen-
tation features of probability of conventional treatment fail-
ing would be most helpful. The data above indicate that
advanced age and hypoalbuminaemia are the major adverse
factors. neither of which would be likely to predispose well to
intensification of therapy. It is more likely that the rate of
response will be a useful indicator. but the logistics of
repeated detailed re-evaluation during therapy are daunting.
Presentation serum $ microglobulin levels, available in a
smaller set of patients, correlated with achievement of com-
plete remission; it remained statistically significant on mul-
tivariate analysis though albumin and stage were not. Amlot
and Adinolfi (1979) found correlation between presentation
f microglobulin levels and initial stage in patients with
Hodgkin's disease. This trend was also confirmed by
Hagberg et al. (1983) and Child et al. (1980). However. there
was no correlation with achievement of remission or survival.
Prognostic effect of P microglobulin on response to therapy
and also on subsequent survival has been documented in
non-Hodgkin's lymphoma and myeloma, but not in Hodg-
kin's disease (Legros et al.. 1987: Han et al.. 1989; Hagberg
et al.. 1983). The cause of elevated A microglobulin levels is
still speculative. It has been suggested that there is increased
shedding due to decreased cell surface expression or due to
increased cell turnover. Swan et al. (1989) suggested that
patients with high A microglobulin had absent cellular exp-
ression of Class I Major Histocompatibility Complex
(MHC). Therefore the prognostic value of serum 3 microg-
lobulin may provide a crude and indirect assessment of the
importance of tumour MHC expression.
The freedom from recurrence pattern for those entering
complete remission is very similar to that reported in the
literature, with most recurrences occurring during the first 3
years, and approximately two-thirds still free of disease 10-15
years from presentation. Limited support for the importance
of dose-intensity comes from the finding that reduction of
more than 15% of the planned cumulative dose over the first
six cycles correlated with a high risk of recurrence. This
interpretation is of course complicated by the inevitable
problem of retrospective analysis. Further, the fact that the
MVPP programme is given evenr 6 weeks compared with 4
weeks for MOPP. and yields identical results in terms of
freedom from recurrence suggests that there may well be a
threshold above which the dose intensity effect becomes
irrelevant. Whether the somewhat lower remission rate in this
study compared with 4-weekly MOPP may reflect the effect
of lower dose intensity is a matter of speculation. Preliminary
results from a Cancer and Leukaemia Group B (CALGB)
study suggest an advantage for ABVD in both inducing and
maintaining remission (Canellos et al.. 1988: Anderson et al..
1990) are interesting and await confirmation. Significant im-
provement in the complete remission, freedom from progres-
sion. relapse-free suryival and overall suryival with alter-
nating MOPP ABVD over MOPP alone has been reported
from Milan. though at a cost of increased treatment related
toxicity (Bonadonna et al.. 1986).
SurVival from recurrence was surprisingly good. and once
again correlated most closely with the response to salvage
therapy. and was characterised for most by repeated recur-
rences with a diminishing likelihood of response. The res-
ponse rate was better following longer first remissions. The
absence of an absolute correlation between duration of first
remission and duration of second remission is surprising.
although the majority of patients with second recurrence
within 2-3 years of apparently successful re-induction
therapy had had initial remission lasting less than 1 year.
This weak correlation, the fact that the median duration of
second remission was 4 years coupled with a median survival
of 4 years from recurrence and 12 years from second remis-
sion makes selection of the most appropriate management at
recurrence difficult. particularly as advancing age (above 40
years) was the only adverse feature identified. It is not yet
clear whether survival following recurrence after non-cross-
resistant alternating or hybrid chemotherapy will follow the
same pattern as following MOPP or MVPP. Further newer
combinations have been shown to be promising (Richards et
al.. 1986).
The published experience with bone marrow ablative
therapy is certainly encouraging. either if used at recurrence
or as consolidation of remission (Carella et al.. 1988: Grib-
ben et al.. 1989: Jagannath et al.. 1989: Jones et al.. 1990).
However, much more data will be required to demonstrate its
general applicability and efficacy. It is less, rather than more.
likely to be relevant to most of the patients who have a
recurrence when over 45 years of age. and this is the group in
greatest need of help. It will clearly take many years to prove436 A.M. OZA et al.
a survival advantage for such treatment at first recurrence or
in second remission: the only valid endpoints of present
studies in the near future will have to be freedom from
recurrence and toxicity. with the hope that if the former is
substantially improved. it will convert into longer survival.
Whether it will be possible to answer the question without
randomised trials is arguable. Minimisation of the short-term
toxicity of treatment. possibly with the use of haemopoietic
growth factors would clearly be most helpful and widen the
range of people in whom therapy could be tested. While it
can be postulated that the successful induction of a second
remission is not an argument for very intensive consolida-
tion, it might well be considered the treatment of choice
following subsequent recurrences. The necessity of identifying
the most appropriate patients to receive experimental therapy
is obvious.
The pattern of survival for the whole population was
obviously dominated by failure of the treatment. with 80%o
of the deaths so far having occurred in people with active
disease. It has previously been reported that almost all of the
men and at least half of the women who survive are sterile
(Sherins & DeVita 1973; Chapman et al.. 1979: 1981: Wax-
man et al.. 1982) and with longer follow-up it is clear that
the incidence of second malignancy continues to increase
(Tester et al.. 1984: Dorreen et al.. 1986: Coleman. 1986:
Tucker et al.. 1988: Kaldor et al.. 1990: Somers et al.. 1990).
Second malignancies accounted for 10% of the deaths in
remitters. being the single most important cause of mortality
after HD. The risk of second malignancy seems to be in-
creased in patients who receive additional therapy-6 7
remitters who develop second malignancy had had extra
chemotherapy as maintenance or additional irradiation.
Three other patients who developed second malignancy fol-
lowing recurrence had been retreated with combination
chemotherapy. The increased risk of secondary malignancy
with increasing therapy is well recognised. particularly fol-
lowing irradiation (Coleman. 1986: Somers et al., 1990). Data
on more than 12.411 patients treated for HD in different
centres were pooled and analysed in 1989 (Somers et al..
1990). The cumulative incidence of second malignancy over a
20-year follow-up period approaches 18.6%0 with solid
tumours' accounting for the majority of late malignancies. In
this group of patients treated with MVPP with a minimum
follow-up of 6 years there has only been one instance of
frank acute myeloid leukaemia which occurred at the same
time as progressive Hodgkin's disease at second recurrence.
and one myelodysplastic syndrome in third remission. In the
NCI series (Longo et al.. 1986). there were 13 cases of acute
leukaemia. from a total cohort of 198 patients, 12 of which
occurred in patients who had received both MOPP and
irradiation. In contrast to these results. Kaldor et al. (19%).
in a case controlled study of 163 cases of leukaemia following
therapy for Hodgkin's disease. found no increased risk in
patients receiving additional irradiation. In the same study.
treatment with more than six cycles significantly increased
the risk of secondary acute leukaemia. The Stanford data
suggest that the risk of acute leukaemia reaches a plateau at
10 years. at 3.3%. though the risk of secondarv non-
Hodgkin's lymphoma continues to increase. The cumulative
actuarial risk of all second cancers from the Stanford series is
17.6% at 15 vears (Tucker et al.. 1988). The cumulative risk
of acute leukaemia in this present series is thus lower than
that reported with a number of series using MOPP. Whether
this is a consequence of the lower intensitv with which
MVPP is administered. being 6-weekly instead of 4-weekly.
needs to be determined.
The long-term toxicity of the newer treatments. either
without alkylating agents. or including them in lower doses
in the form of hybrid or alternating programmes. may well
be much less than that of MOPP alone. Much will have been
gained even if this is the only achievement of modifying the
initial therapy. Reducing its duration was certainlv a benefit.
Neither the failure of MOPP like therapy to elirminate HD
from some patients nor its late toxicity. even fatal for others.
should be allowed to detract from the significant benefit it
has brought to the majority of those who received it. The
challenge is to look forward and do better.
Appendix
Dose reduction
Percentage of planned dose administered
TMustine + - Vinblastine +
T Procarbazine + - PredIisolone
x 100
4
T = total dose administered. P = planned dose.
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